(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme a and response to atorvastatin in coronary artery disease patients

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 3, 2009, Pages 211-215

  Noriega, Viviana ^b,c   Pennanen, Christian ^b,c   Sánchez, María Pilar ^c   Chiong, Mario ^b,c   Llancaqueo, Marcelo ^a   Lavandero, Sergio ^a,c,d   Prieto, Juan Carlos ^a,d  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b FONDAP   (Chile)

^c Faculty of Chemical and Pharmaceutical Sciences

^d Faculty of Medicine   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYMINE; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TANDEM REPEAT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALLELES; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PYRROLES; TRIGLYCERIDES; TRINUCLEOTIDE REPEATS;

EID: 60349125945     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00341.x     Document Type: Article

References (23)

1. Ridker PM, Rifai N, Clearfiel M. Measurement of C-reactive protein for the targeting of statins therapy in the primary prevention of acute coronary events. N Engl J Med 2001 344 : 1959 65.
2. Albert MA, Danielson E, Rifai N, Ridker PM. Effects of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001 286 : 64 70.
3. Kinlay S, Timmis T, Clark M. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002 89 : 1205 7.
4. Rosenson R. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004 173 : 1 12.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men hypercholesterolemia. N Engl J Med 1995 333 : 1301 7.
6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention Study]. JAMA 1998 279 : 1615 22.
7. Sever PS, Dahlof B, Poulter NR, Dahlof B, Wedel H, Collings R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003 361 : 1149 58.
8. Scandinavian Simvastatin Survival Study Writing Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 335 : 1001 9.
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 57.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002 360 : 7 22.
12. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G et al. Therapy with HMG-CoA reductase inhibitors: characteristics of the long term permanence of hypocholesterolemic activity. Atherosclerosis 1995 117 : 189 98.
13. Chasman D, Posada D, Subrahmanyan L, Cook N, Stanton V, Ridker P. Pharmacogenetics Study of Statin Therapy and cholesterol reduction. JAMA 2004 291 : 2821 7.
14. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomic J 2005 5 : 352 8.
15. Tong Y, Zhang S, Li H, Su Z, Kong X, Liu H et al. 8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease. Lipid 2004 39 : 239 41.
16. Hubacek JA, Pistulkova H, Valenta Z, Poledne R. (TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia. Vasa 1999 28 : 169 71.
17. Plat J, Mensink RP. Relationship of genetic variation in genes ecoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption. Eur J Clin Invest 2002 32 : 242 50.
18. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999 45 : 2136 41.
19. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using AchE as label: an alternative to radioimmunoassay. Anal Chem 1985 57 : 1170 3.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
21. Lalovic A, Sequeira A, DeGuzman R, Chawky N, Lesege A, Seguin M et al. Investigation of completed suicide and genes involved in cholesterol metabolism. J Affect Disord 2004 79 : 25 32.
22. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 (Suppl. 1 III 39 43.
23. Kom GD, Schwedhelm E, Maas R, Schneider L, Benndorf R, Boger RH. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patient. Br J Clin Pharmacol 2007 63 : 672 9.